| Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. | |
| | |
MedLine Citation:
|
PMID: 20070395 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Aim: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Therefore we needed to establish a new regimen without ribavirin. Methods: We devised a new regimen (same-day beta/alpha2b) to administer IFN-beta and alpha2b on the same-day, and compared it with IFN-alpha2b alone and IFN-alpha2b plus ribavirin. The cases were 36 patients (26.1%) in whom ribavirin could not be used (young women, anemia, etc.) among 138 patients who underwent IFN treatment after ribavirin release. Results: The percentages of patients withdrawing due to side-effects were 6.8%, 18.8% and 17.0% in the treatment with same-day beta/alpha2b, IFN-alpha2b alone and IFN-alpha2b plus ribavirin groups, respectively. In genotype 1b, the sustained viral response (SVR) was 28.6% (4/14), 13.6% (3/22) and 25.0% (8/32) with a high viral load, and 91.7% (11/12), 27.3% (3/11) and 57.1% (4/7) with a low viral load for the respective groups. According to a study on viral half-life during the early phase of IFN therapy, there was no difference among the regimens of same-day IFN-beta/alpha2b, beta alone, alpha2b alone and twice-daily treatment with IFN-beta. Same-day beta/alpha2b treatment showed a significantly higher SVR rate in moving type patients with a genotype 1b/high viral load. Conclusions: Same-day beta/alpha2b treatment resulted in few cases where therapy was discontinued and showed a high SVR rate. This regimen is especially appropriate in cases where ribavirin has been deemed unsuitable. |
| | |
Authors:
|
Eiichi Tomita; Kazuki Ando; Jun-Ichi Sugihara; Youichi Nishigaki; Tetsuya Yamada; Ryoko Ando; Masao Takemura; Mitsuru Seishima |
Related Documents
:
|
1355475 - Psychophysiologic response during script-driven imagery as an outcome measure in posttr... 19541575 - Switch from a zdv/3tc-based regimen to a completely once daily (qd) regimen of emtricit... 19669285 - Sustained response to peginterferon alfa-2a (40 kd) with or without lamivudine in asian... 20662655 - Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pil... 15151525 - Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. 326595 - An open comparative trial of vanquin tablets and pripsen granules in the treatment of t... |
Publication Detail:
|
Type: Journal Article Date: 2010-01-11 |
Journal Detail:
|
Title: Hepatology research : the official journal of the Japan Society of Hepatology Volume: 40 ISSN: 1386-6346 ISO Abbreviation: Hepatol. Res. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-04-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9711801 Medline TA: Hepatol Res Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 261-8 Citation Subset: - |
Affiliation:
|
Gastroenterology and Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu City, Gifu 500-8513, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Over-expression of Toll-like receptors and their ligands in small-for-size graft.
Next Document: Serum HGF and TGF-beta1 levels after right portal vein embolization.